UNSPSC 51285502: Clofoctol

This classification denotes an anti-infective agent with the molecular formula C21H26Cl2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 704083NI0R, chemically known as 2-((2,4-dichlorophenyl)methyl)-4-(1,1,3,3-tetramethylbutyl)phenol but generally known as clofoctol, which bears US NIH Compound Identifier 2799. European Medicines Agency schedules Clofoctol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06711MIG.

UNSPSC 51285502 Clofoctol is a Commodity code under which state and local governments procure pharmaceutical and medical supply products, though recent solicitations indicate activity focused on naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and medical emergency supplies rather than clofoctol specifically. The issuing bodies soliciting under this code span county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances serving multiple jurisdictions. Work solicited includes procurement of naloxone and related overdose-response products for community health programs, direct-to-manufacturer pharmaceutical distribution arrangements, generic pharmaceutical supply contracts for state and local facilities, and emergency medical supplies for first-responder use. Quantities and scope vary significantly — from thousands of units of naloxone annually to comprehensive pharmaceutical catalogs with hundreds of line items.

Recent activity appears concentrated in Florida and Minnesota, with additional procurement intelligence gathering in Texas. Seminole County, Florida released an IFB (Solicitation IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building. The City of Tampa issued an IFB (Bid 26P00145, due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000, designated as a sheltered-market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers across participating state and local facilities, with products required available by May 15, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities regarding direct-to-manufacturer prescription programs, indicating preliminary-stage market research before formal solicitation.